AFC-HD AMS Life Science Co

AFC-HD AMS Life Science Co EBIT per Share

The EBIT per Share of AFC-HD AMS Life Science Co (2927.T) as of Nov 4, 2026 is 155.64 JPY. In the previous year, EBIT per Share was 167.16 JPY — a change of -6.89% (lower).

EBIT per Share

155.64JPY

YoY

-6.89%

Last updated:

EBIT per Share of AFC-HD AMS Life Science Co is 2026 155.64 JPY. EBIT per Share of AFC-HD AMS Life Science Co was 2025 167.16 JPY. It decreases by -6.89% lower compared to the previous year.

The AFC-HD AMS Life Science Co EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2020
78.38 JPY
Jan 1, 2021
157.67 JPY
Jan 1, 2022
72.25 JPY
Jan 1, 2023
117.10 JPY
Jan 1, 2024
136.17 JPY
Jan 1, 2025
167.16 JPY
Jan 1, 2026
155.64 JPY
Jan 1, 2027 (e)
0.00 JPY
The AFC-HD AMS Life Science Co EBIT per Share history
YEAREBIT per ShareYoY
est0.00JPY-100.00%
155.64JPY-6.89%
167.16JPY+22.76%
136.17JPY+16.29%
117.10JPY+62.08%
72.25JPY-54.18%
157.67JPY+101.16%
78.38JPY+12.34%
69.77JPY-4.12%
72.77JPY-17.59%
88.30JPY+20.03%
73.57JPY-6.34%
78.55JPY+66.12%
47.29JPY-37.74%
75.95JPY+27.28%
59.67JPY-30.58%
85.96JPY+33.42%
64.43JPY+4.62%
61.58JPY-13.17%
70.92JPY+73.15%
40.96JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AFC-HD AMS Life Science Co Stock analysis

What does AFC-HD AMS Life Science Co do? AFC-HD AMS Life Science Co., Ltd. generates revenue through its Healthcare segment, which produces and sells health foods, cosmetics, and OEM services for other brands. The Pharmaceutical segment manufactures and sells ethical drugs, over-the-counter drugs, and generic medicines. The company also manages restaurants via a subsidiary, contributing to its diversified income streams. Customers include businesses seeking OEM partnerships and consumers purchasing health and pharmaceutical products. The firm's products are sold under its own brand and through OEM agreements, targeting both individual consumers and corporate clients. The Healthcare segment focuses on wellness products, while the Pharmaceutical segment caters to medical needs with prescription and non-prescription drugs. The restaurant management subsidiary provides additional revenue from food service operations. Revenue is derived from the sale of health foods, cosmetics, Chinese medicine medicines, general medicines, and healthcare products within the Healthcare segment. The Pharmaceutical segment's income comes from ethical drugs, over-the-counter drugs, and generic medicines. The restaurant subsidiary's operations further support the company's financial structure through food service sales. AFC-HD AMS Life Science Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AFC-HD AMS Life Science Co stock

EBIT per Share of AFC-HD AMS Life Science Co is 155.64 JPY in 2026.

EBIT per Share of AFC-HD AMS Life Science Co changed from 167.16 JPY to 155.64 JPY, representing a -6.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share AFC-HD AMS Life Science Co since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — AFC-HD AMS Life Science Co

All Key Metrics — AFC-HD AMS Life Science Co